Cure My Disease

Don't miss your cure!

 Log in / Sign up

New hope for anemia patients: drug shows promise in Late-Stage trial

NCT ID NCT05648968

Ongoing Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Oct 31, 2025 · Last updated May 14, 2026 · Updated 25 times

Summary

This study tests a new drug called ianalumab in people with a rare type of anemia (warm autoimmune hemolytic anemia) that hasn't improved with at least one prior treatment. About 90 adults will receive either the drug or a placebo to see if it can raise hemoglobin levels and keep them stable for at least eight weeks. The goal is to control the disease, not cure it, as ongoing management may still be needed.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for WARM AUTOIMMUNE HEMOLYTIC ANEMIA (WAIHA) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Fred Hutchinson Cancer Center

    Seattle, Washington, 98109, United States

  • Michigan Center of Medical Research

    Farmington Hills, Michigan, 48334, United States

  • Novartis Investigative Site

    CABA, Buenos Aires, C1414DRK, Argentina

  • Novartis Investigative Site

    Caba, C1015ABO, Argentina

  • Novartis Investigative Site

    Caba, C1039AAC, Argentina

  • Novartis Investigative Site

    Garran, Australian Capital Territory, 2605, Australia

  • Novartis Investigative Site

    Melbourne, Victoria, 3004, Australia

  • Novartis Investigative Site

    Guangzhou, Guangdong, 510515, China

  • Novartis Investigative Site

    Hangzhou, Zhejiang, 310003, China

  • Novartis Investigative Site

    Dalian, 116000, China

  • Novartis Investigative Site

    Tianjin, 300020, China

  • Novartis Investigative Site

    Tianjin, 300052, China

  • Novartis Investigative Site

    Créteil, 94010, France

  • Novartis Investigative Site

    Lille, 59037, France

  • Novartis Investigative Site

    Nantes, 44093, France

  • Novartis Investigative Site

    Nice, 06202, France

  • Novartis Investigative Site

    Dresden, 01307, Germany

  • Novartis Investigative Site

    Essen, 45147, Germany

  • Novartis Investigative Site

    Giessen, 35392, Germany

  • Novartis Investigative Site

    Hanover, 30161, Germany

  • Novartis Investigative Site

    Debrecen, Hajdu Bihar Megye, 4032, Hungary

  • Novartis Investigative Site

    New Delhi, National Capital Territory of Delhi, 110029, India

  • Novartis Investigative Site

    Madurai, Tamil Nadu, 625107, India

  • Novartis Investigative Site

    Hyderabad, Telangana, 500082, India

  • Novartis Investigative Site

    Lucknow, Uttar Pradesh, 226014, India

  • Novartis Investigative Site

    Kfar Saba, 4428164, Israel

  • Novartis Investigative Site

    Petah Tikva, 4941492, Israel

  • Novartis Investigative Site

    Milan, MI, 20100, Italy

  • Novartis Investigative Site

    Milan, MI, 20122, Italy

  • Novartis Investigative Site

    Bassano del Grappa, VI, 36061, Italy

  • Novartis Investigative Site

    Novara, 28100, Italy

  • Novartis Investigative Site

    Narita, Chiba, 286-8523, Japan

  • Novartis Investigative Site

    Matsuyama, Ehime, 7900024, Japan

  • Novartis Investigative Site

    Gifu, Gifu, 501-1194, Japan

  • Novartis Investigative Site

    Kobe, Hyōgo, 6500047, Japan

  • Novartis Investigative Site

    Isehara, Kanagawa, 259-1193, Japan

  • Novartis Investigative Site

    Suita, Osaka, 5650871, Japan

  • Novartis Investigative Site

    Itabashi-ku, Tokyo, 1738610, Japan

  • Novartis Investigative Site

    Shinjuku Ku, Tokyo, 160-0023, Japan

  • Novartis Investigative Site

    George Town, Pulau Pinang, 10450, Malaysia

  • Novartis Investigative Site

    Kuching, Sarawak, 93586, Malaysia

  • Novartis Investigative Site

    Johor Bahru, 80100, Malaysia

  • Novartis Investigative Site

    Singapore, 119074, Singapore

  • Novartis Investigative Site

    Singapore, S308433, Singapore

  • Novartis Investigative Site

    Barcelona, 08035, Spain

  • Novartis Investigative Site

    Murcia, 30008, Spain

  • Novartis Investigative Site

    Bangkok, 10330, Thailand

  • Novartis Investigative Site

    Bangkok, 10700, Thailand

  • Novartis Investigative Site

    Chiang Mai, 50200, Thailand

  • Novartis Investigative Site

    Birmingham, West Midlands, B15 2TH, United Kingdom

  • Novartis Investigative Site

    Leeds, LS1 3EX, United Kingdom

  • Novartis Investigative Site

    London, W12 0HS, United Kingdom

  • University of Minnesota Med Center

    Minneapolis, Minnesota, 55455, United States

Conditions

Explore the condition pages connected to this study.

WARM AUTOIMMUNE HEMOLYTIC ANEMIA (WAIHA)